ChiCTR2000036386 版本V1.3 版本创建时间2020/09/10 11:51:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000036386 

最近更新日期:

Date of Last Refreshed on:

2020-09-10 09:40:33 

注册时间:

Date of Registration:

2020-08-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

孕中期外周血B淋巴细胞比例及IgA抗体水平与妊娠期糖尿病预后相关性的临床研究

Public title:

Clinical study on the relationship between B lymphocyte ratio and IgA antibody level in the second trimester of pregnancy and the prognosis of gestational diabetes mellitus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

孕中期外周血B淋巴细胞比例及IgA抗体水平与妊娠期糖尿病预后相关性的临床研究

Scientific title:

Clinical study on the relationship between B lymphocyte ratio and IgA antibody level in the second trimester of pregnancy and the prognosis of gestational diabetes mellitus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

庄研 

研究负责人:

庄研 

Applicant:

Yan Zhuang 

Study leader:

Yan Zhuang 

申请注册联系人电话:

Applicant telephone:

+86 13761562832

研究负责人电话:

Study leader's telephone:

+86 13761562832

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yan.zhuang@shgh.cn

研究负责人电子邮件:

Study leader's E-mail:

yan.zhuang@shgh.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市海宁路100号

研究负责人通讯地址:

上海市海宁路100号

Applicant address:

100 Haining Road, Hongkou District, Shanghai

Study leader's address:

100 Haining Road, Hongkou District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第一人民医院

Applicant's institution:

Shanghai General Hospital

研究负责人所在单位:

上海市第一人民医院

Affiliation of the Leader:

Shanghai General Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020KY087

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第一人民医院人体试验伦理审查委员会

Name of the ethic committee:

Ethical Review Committee of Human Experiment of Shanghai First People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-19 00:00:00

伦理委员会联系人:

金舒静

Contact Name of the ethic committee:

Shujing Jin

伦理委员会联系地址:

中国上海海宁路100号

Contact Address of the ethic committee:

100 Haining Road, Hongkou District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第一人民医院

Primary sponsor:

Shanghai General Hospital

研究实施负责(组长)单位地址:

上海海宁路100号

Primary sponsor's address:

100 Haining Road, Hongkou District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一人民医院

具体地址:

海宁路100号

Institution
hospital:

Shanghai General Hospital

Address:

100 Haining Road, Hongkou District

经费或物资来源:

促进市级医院临床技能与临床创新三年行动计划(2020-2022年 重大临床研究项目

Source(s) of funding:

Three year action plan for promoting clinical skills and clinical innovation in municipal hospitals (major clinical research projects in 2020-2022

Target disease:

gestational diabetes mellitus

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

探索妊娠期糖尿病孕妇外周血B淋巴细胞比例及IgA抗体水平对妊娠期糖尿病预后的评估价值。  

Objectives of Study:

To explore the evaluation value of the percentage of peripheral blood B lymphocytes and the level of IgA antibodies in pregnanct women with gestational diabetes mellitus.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

于我院正规产检并分娩,年龄在25-35岁之间,无既往糖尿病病史的育龄期妇女可纳入该研究。

Inclusion criteria

Women of childbearing age, aged between 25 and 35 years old, with no previous history of diabetes in our hospital will be include in this study.

排除标准:

以下几类孕妇将不被纳入该项研究:
① 年龄≦18岁,或≥35岁的孕妇;
② 既往有糖尿病病史;
③ 孕期OGTT检查提示为PGDM者,即:空腹血浆葡萄糖≥7.0mmol/L;或75g口服葡萄糖耐量试验服糖后2h血糖≥11.1mmol/L;或伴有典型的高血糖症状或高血糖危象,同时随机血糖≥11.1mmol/L;或糖化血红蛋白≥6.5%。
④ 患有妊娠期高血压疾病,自身免疫性疾病如系统性红斑狼疮等的孕妇。

Exclusion criteria:

The following categories of pregnant women will not be included in the study:
1. Pregnant women with age <= 18 years old or >= 35 years old;
2. Women with previous history of diabetes;
3. OGTT examination during pregnancy indicates PGDM, that is: fasting plasma glucose >= 7.0mmol/l; or 75g oral glucose tolerance test 2 hours after taking glucose >= 11.1mmol/l; or accompanied by typical hyperglycemia symptoms or hyperglycemic crisis, and random blood glucose >= 11.1mmol/l; or glycosylated hemoglobin >= 6.5%.
4. Pregnant women with gestational hypertension, autoimmune diseases such as systemic lupus erythematosus, etc.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2021-10-31 00:00:00  

干预措施:

Interventions:

组别:

血糖正常组 vs 糖耐量受损组 vs 空腹血糖受损组 vs 糖尿病组

样本量:

1200

Group:

Normal glucose group versus impaired glucose tolerance group versus impaired fasting glucose group versus diabetes group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

B淋巴细胞比例

指标类型:

主要指标

Outcome:

B lymphocyte ratio

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

IgA 抗体水平

指标类型:

主要指标

Outcome:

IgA antibody level

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023.3.10 http://chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2023.3.10 http://chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统,ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-22 20:56:44